CA2871996A1 - Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer - Google Patents

Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer Download PDF

Info

Publication number
CA2871996A1
CA2871996A1 CA2871996A CA2871996A CA2871996A1 CA 2871996 A1 CA2871996 A1 CA 2871996A1 CA 2871996 A CA2871996 A CA 2871996A CA 2871996 A CA2871996 A CA 2871996A CA 2871996 A1 CA2871996 A1 CA 2871996A1
Authority
CA
Canada
Prior art keywords
gasp
cancer
subject
expression level
early stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871996A
Other languages
English (en)
Inventor
Frank N. Chang
George P. Tuszynski
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/464,174 external-priority patent/US8420333B2/en
Priority claimed from US13/800,741 external-priority patent/US8980269B2/en
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of CA2871996A1 publication Critical patent/CA2871996A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de détermination de savoir si un cancer de stade précoce est présent chez un sujet, comprenant la détection du niveau d'expression de GASP-1 chez le sujet par détection de la quantité de fragments de peptide GASP- 1 présente dans un échantillon biologique du sujet. Parce que le cancer peut être détecté à un stade précoce, le ciblage thérapeutique peut être amorcé avant que le cancer n'atteigne un stade plus tardif (par exemple avant le développement de symptômes apparents). Une méthode de traitement du cancer à un stade précoce chez un sujet comprend l'administration au sujet d'une quantité efficace d'un inhibiteur de GASP-1 pour inhiber la progression du cancer de stade précoce en un cancer de stade plus tardif. Un ELISA compétitif pouvant détecter des fragments de peptide GASP-1 à une concentration inférieure à 1 ng/ml a été développé.
CA2871996A 2012-05-04 2013-05-03 Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer Abandoned CA2871996A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/464,174 2012-05-04
US13/464,174 US8420333B2 (en) 2009-07-14 2012-05-04 G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
US13/800,741 2013-03-13
US13/800,741 US8980269B2 (en) 2009-07-14 2013-03-13 G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
PCT/US2013/039430 WO2013166364A1 (fr) 2012-05-04 2013-05-03 Protéine de tri 1 associée à un récepteur couplé à une protéine g en tant que biomarqueur du cancer

Publications (1)

Publication Number Publication Date
CA2871996A1 true CA2871996A1 (fr) 2013-11-07

Family

ID=49514902

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871996A Abandoned CA2871996A1 (fr) 2012-05-04 2013-05-03 Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer

Country Status (5)

Country Link
EP (1) EP2845008A4 (fr)
AU (1) AU2013256109A1 (fr)
CA (1) CA2871996A1 (fr)
TW (1) TW201400498A (fr)
WO (1) WO2013166364A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104330570B (zh) * 2014-10-11 2016-03-16 中国科学院微生物研究所 人热休克蛋白gp96在制备筛查肝病的产品中的应用
CA3099974A1 (fr) 2018-05-11 2019-11-14 Halcyon Therapeutics, Inc. Proteines de liaison et lymphocytes t de recepteur antigenique chimerique ciblant des granules de gasp-1 et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056523A2 (fr) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Procedes de diagnostic et de surveillance de la progression d'un cancer
CA2716522A1 (fr) * 2008-03-05 2009-10-15 Singulex, Inc. Procedes et compositions pour une detection hautement sensible de molecules
EP2454280A2 (fr) * 2009-07-14 2012-05-23 Temple University Of The Commonwealth System Of Higher Education Marqueurs dans le sérum associés à des stades précoces et à d'autres stades d'un cancer du sein

Also Published As

Publication number Publication date
WO2013166364A1 (fr) 2013-11-07
EP2845008A4 (fr) 2016-03-23
AU2013256109A1 (en) 2014-12-04
EP2845008A1 (fr) 2015-03-11
TW201400498A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
CN107326066A (zh) 用于膀胱癌检测的尿标记物
US9182415B2 (en) Use of IMP3 as a prognostic marker for cancer
CN102687011B (zh) 癌症生物标志物及其应用
MX2012000921A (es) Marcadores para cancer endometrial.
CN104204807A (zh) 用于胃癌的生物标志物及其应用
Chang et al. Expression and clinical significance of NEDD9 in lung tissues
US10338076B2 (en) Methods and compositions for the diagnosis of ovarian cancer
US8980269B2 (en) G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
JP2022058635A (ja) 大腸癌の検出及び処置方法
US8420333B2 (en) G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
Jung et al. The HCCR oncoprotein as a biomarker for human breast cancer
CN106164676B (zh) 针对pd-l1的srm测定
WO2004085676A1 (fr) Methode de detection in vitro du carcinome a cellules transitionnelles de la vessie
US20070264643A1 (en) Compositions and Methods Relating to CNS Lymphoma
CA2871996A1 (fr) Proteine de tri 1 associee a un recepteur couple a une proteine g en tant que biomarqueur du cancer
US20150011411A1 (en) Biomarkers of cancer
US20190016821A1 (en) Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
US20090233295A1 (en) Trim59 directed diagnostics for neoplastic disease
JP2022153482A (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
WO2017219093A1 (fr) Procédés de criblage
US20240384353A1 (en) Methods of treating pancreatic cancer
EP4650779A1 (fr) Biomarqueur pour le diagnostic ou le pronostic du carcinome pulmonaire à cellules squameuses à l'aide d'exosomes et son utilisation
CN109971854B (zh) 用于开发宫颈疾病的诊疗产品的靶分子
US20090233293A1 (en) Ttk directed diagnostics for neoplastic disease
US20090068669A1 (en) Slc9a3r1 directed diagnostics for neoplastic disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180417

FZDE Discontinued

Effective date: 20200831